This article is more than 5 years old. Information may no longer be current.

AcuFocus announces $65 million in financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — AcuFocus, manufacturer of the Kamra intracorneal inlay, announced that it has raised $65 million in funding, according to a press release.

The Kamra inlay is being used for treatment of presbyopia in select markets in Europe, South America, the Asia-Pacific region and the Middle East. More than 7,000 inlays have already been implanted worldwide, according to the release.

AcuFocus will use the funding to help expand markets for the device. Cowen Royalty led this round of financing.

"We are thrilled with this financial support from Cowen Royalty and our existing investors as we prepare to submit to the FDA early 2012," Ed Peterson, AcuFocus president and CEO, said in the release. "This funding gives us the ability to scale our business by expanding commercially into new and existing markets on a global basis."

"Previously, there has been no real solution for presbyopia, but I believe that the Kamra inlay now fills this gap," Richard Lindstrom, MD, OSN Chief Medical Editor, said. "With 80% of refractive procedures occurring outside of the U.S., the Kamra inlay is clearly a global business."